Pilocarpine
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
Pilocarpine: From Unrecorded Original Indication to Primary Hereditary Glaucoma
One-Sentence Summary
No original indication or licensing data is on file for Pilocarpine (DrugBank DB01085) in this dataset, and the drug is currently not marketed in this jurisdiction. The TxGNN model predicts it may be effective for Primary Hereditary Glaucoma, with a prediction score of 99.83%, but no clinical trials or literature currently support this direction — the signal is model-only at this stage.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | No records available (no license or indication data on file) |
| Predicted New Indication | Primary Hereditary Glaucoma |
| TxGNN Prediction Score | 99.83% (rank 4905) |
| Evidence Level | L5 (model prediction only, no supporting trials/literature) |
| US Market Status | Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, no structured mechanism of action (MOA) data is on file for this drug. However, the model’s own repurposing rationale draws on established pharmacology: Pilocarpine is a muscarinic (M3) receptor agonist acting on the ciliary muscle and iris sphincter. It induces miosis and increases aqueous humor outflow through the trabecular meshwork — the classic pharmacological mechanism for lowering intraocular pressure.
This mechanism maps directly onto glaucoma pathophysiology, where impaired aqueous humor drainage raises intraocular pressure. Notably, pilocarpine is historically a well-established miotic agent used in glaucoma management, so this “predicted new indication” largely reflects a long-standing, mechanistically mature use rather than a novel therapeutic hypothesis. That said, this dataset contains no original indication, license, or literature records to formally substantiate that history — it is asserted only through the model’s mechanistic rationale field, not through verifiable regulatory or bibliographic evidence.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is high, but evidence level is L5 — no clinical trials, no literature, and no verified original-indication or MOA documentation exist in this dataset to corroborate the model’s mechanistic rationale. A blocking data gap (missing TFDA/label warnings and contraindications) also prevents any safety pre-screening (S1).
To proceed, the following is needed:
- TFDA (or equivalent) label warnings and contraindications — currently blocking safety review
- Verified mechanism of action (MOA) documentation from DrugBank or equivalent source
- Confirmed original indication(s) and licensing history for this drug
- At least preliminary clinical or literature evidence directly linking pilocarpine to glaucoma treatment, to move the evidence level beyond L5
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.